

CITATION REPORT

List of articles citing

A Sustained Virological Response to Interferon or Interferon/Ribavirin Reduces Hepatocellular Carcinoma and Improves Survival in Chronic Hepatitis C: A Nationwide, Multicentre Study in Taiwan

DOI: 10.1177/135965350601100811
Antiviral Therapy, 2006, 11, 985-994.

Source: <https://exaly.com/paper-pdf/145790103/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
137	Long-term effects of interferon-based therapy for chronic hepatitis C. 2007 , 72 Suppl 1, 16-23		29
136	Reply:. <i>Hepatology</i> , 2007 , 45, 1587-1588	11.2	2
135	Liver cancer and hepatitis B and C in New South Wales, 1990-2002: a linkage study. 2007 , 31, 475-82		26
134	Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan. 2007 , 25, 1029-37		58
133	Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma. 2008 , 80, 1354-62		26
132	Community-based mass ultrasonographic screening of hepatocellular carcinoma among thrombocytopenic adults. 2008 , 17, 1813-21		18
131	The clinical management of hepatic neoplasms. 1-24		1
130	Hepatocellular carcinoma in a hepatitis C patient with sustained viral response and no fibrosis. 2009 , 8, 64-67		4
129	Geographic variations of predominantly hepatitis C virus associated male hepatocellular carcinoma townships in Taiwan: identification of potential high HCV endemic areas. 2009 , 3, 537-43		9
128	Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice. 2009 , 29, 1000-10		18
127	Splenectomy and antiviral treatment for thrombocytopenic patients with chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2010 , 17, 488-92	3.4	11
126	Prevention of hepatocellular carcinoma complicating chronic hepatitis C. 2009 , 24, 531-6		32
125	Treatment of chronic hepatitis C in Asia: when East meets West. 2009 , 24, 336-45		203
124	Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. 2009 , 136, 138-48		481
123	Effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis. 2009 , 39, 432-8		26
122	Antitumor activity of type I and type III interferons in BNL hepatoma model. 2010 , 59, 1059-71		88
121	Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. 2010 , 4, 439-74		825

120	Performance of two Real-Time RT-PCR assays for quantitation of hepatitis C virus RNA: evaluation on HCV genotypes 1-4. 2010 , 82, 1878-88		19
119	Enhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registry. 2010 , 32, 535-42		12
118	Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening. 2010 , 25, 1426-34		27
117	A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. 2010 , 8, 280-8, 288.e1		275
116	Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. 2010 , 8, 192-9		164
115	Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. <i>Journal of Hepatology</i> , 2010 , 52, 889-94	13.4	105
114	Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. 2011 , 9, 923-30		57
113	Redefining baseline demographics: the role of genetic testing in hepatitis C virus infection. 2011 , 15, 497-513		13
112	Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. 2011 , 140, 840-9; quiz e12		162
111	Hepatocellular carcinoma in 2011 and beyond: from the pathogenesis to molecular targeted therapy. 2011 , 81 Suppl 1, 1-10		18
110	Chronic hepatitis C infection in the elderly. 2011 , 27, 533-7		18
109	A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. 2011 , 9, 509-516.e1		370
108	Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon- α 2a and ribavirin in HIV/HCV co-infected patients. <i>Journal of Hepatology</i> , 2011 , 54, 41-7	13.4	18
107	The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies - a multicenter prospective trial. <i>Journal of Hepatology</i> , 2011 , 54, 219-26	13.4	21
106	Cancer preventive effect of pegylated interferon α 2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis. 2011 , 41, 955-64		16
105	The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy. <i>Antiviral Therapy</i> , 2011 , 16, 677-84	1.6	34
104	Does antiviral therapy prevent hepatocellular carcinoma?. <i>Antiviral Therapy</i> , 2011 , 16, 787-95	1.6	25
103	Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma?. 2011 , 26, 221-7		43

102	Liver interleukin-8 messenger RNA expression and interferon sensitivity-determining region mutations relate to treatment response in hepatitis C 1b. <i>Antiviral Therapy</i> , 2011 , 16, 825-32	1.6	6
101	Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis. 2011 , 56, 1853-61		35
100	Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. 2011 , 16, 210-20		39
99	Fighting against viral hepatitis: lessons from Taiwan. <i>Hepatology</i> , 2011 , 54, 381-92	11.2	52
98	Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. 2011 , 128, 2344-52		72
97	Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. 2011 , 52, 889-900		187
96	Occurrence of hepatocellular carcinoma was not a rare event during and immediately after antiviral treatment in Japanese HCV-positive patients. 2011 , 80, 366-72		12
95	Hospital- and community-based screenings for hepatocellular carcinoma in Taiwan. 2011 , 81 Suppl 1, 36-40		12
94	Interferon lambda: a new sword in cancer immunotherapy. 2011 , 2011, 349575		56
93	Treatment of patients with HCV related cirrhosis: many rewards with very few risks. <i>Hepatitis Monthly</i> , 2012 , 12, 361-8	1.8	7
92	Predictors of changes in hemoglobin levels in patients with chronic hepatitis C treated with ribavirin plus pegylated interferon- α 2012 , 34, 429-34		9
91	Anticarcinogenic impact of interferon therapy on the progression of hepatocellular carcinoma in patients with chronic viral infection. 2012 , 42, 22-32		7
90	Surveillance for hepatocellular carcinoma. 2012 , 39, 384-98		50
89	Long-term health outcomes of chronic hepatitis C patients: A review of findings from REVEAL-HCV cohort study. 2012 , 2, 99-107		2
88	Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense. <i>Journal of Hepatology</i> , 2012 , 57, 1326-35	13.4	22
87	A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regression. 2012 , 82, 275-89		29
86	Thyroid autoantibodies and dysfunction do not impact the treatment efficacy of peginterferon and ribavirin combination therapy in chronic hepatitis C. 2012 , 6, 613-9		4
85	APASL consensus statements and management algorithms for hepatitis C virus infection. 2012 , 6, 409-35		139

84	Long-term cohort study of chronic hepatitis C according to interferon efficacy. 2012 , 27, 291-9		22
83	Decreased anti-hepatitis C virus titer and associated factors in chronic hepatitis C patients after sustained virological response: a prospective study. 2012 , 27, 1106-11		10
82	The safety and efficacy of peginterferon plus ribavirin in hepatitis C patients concomitant with malignancy other than hepatocellular carcinoma: a multicenter study. 2013 , 7, 180-7		2
81	Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. <i>Hepatology</i> , 2013 , 57, 2135-42	11.2	55
80	Host factors determining the efficacy of hepatitis C treatment. 2013 , 48, 22-30		24
79	Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin. 2013 , 28, 1515-20		14
78	Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. <i>Hepatology</i> , 2013 , 58, 150-7	11.2	65
77	Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients. 2013 , 33, 756-61		40
76	Treatment of patients with dual hepatitis C and B by peginterferon and ribavirin reduced risk of hepatocellular carcinoma and mortality. 2014 , 63, 506-14		38
75	Improved Serum Alpha-Fetoprotein Levels after Iron Reduction Therapy in HCV Patients. 2014 , 2014, 875140		3
74	Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection. 2014 , 29, 1012-8		8
73	Did postoperative peg-interferon plus ribavirin really reduce recurrence of hepatitis C virus-related hepatocellular carcinoma?. <i>Hepatology</i> , 2014 , 59, 1652	11.2	
72	Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. <i>Journal of Hepatology</i> , 2014 , 61, 67-74	13.4	91
71	Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. 2014 , 26, 78-88		119
70	The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients. 2015 , 30, 1768-74		12
69	Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan. <i>Medicine (United States)</i> , 2015 , 94, e690	1.8	71
68	Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 19698-712	6.3	46
67	Interferon-based therapy delays but metabolic comorbidity accelerates progression of chronic hepatitis C. 2015 , 14, 36-45		0

66	Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response. 2015 , 61, 730-40		190
65	The changing epidemiology of Asian digestive cancers: From etiologies and incidences to preventive strategies. 2015 , 29, 843-53		17
64	Hepatitis C virus infection, antiviral therapy, and risk of hepatocellular carcinoma. 2015 , 42, 329-38		17
63	Oncogenic viruses and hepatocellular carcinoma. 2015 , 19, 341-60		14
62	Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. 2015 , 15, 19		118
61	Why is viral eradication so important in patients with HCV-related cirrhosis?. <i>Antiviral Therapy</i> , 2017 , 22, 1-12	1.6	6
60	APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. 2016 , 10, 681-701		60
59	HCC: Where Does HCV Therapy Play a Role?. 2016 , 15, 17-25		1
58	Surveillance for Hepatocellular Carcinoma. 2016 , 339-354		1
57	Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression?. 2016 , 36, 783-90		25
56	Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon- α and ribavirin therapy. <i>Journal of Viral Hepatitis</i> , 2016 , 23, 971-976	3-4	9
55	Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1. 2016 , 44, 738-46		10
54	IFN- α cancer immunotherapy: new kid on the block. 2016 , 8, 877-88		21
53	Hepatocellular Carcinoma and Hepatitis C Virus. 2016 , 109-136		1
52	Perspectives on dual hepatitis B and C infection in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2016 , 115, 298-305	3.2	10
51	A real-world impact of cost-effectiveness of pegylated interferon/ribavirin regimens on treatment-naïve chronic hepatitis C patients in Taiwan. 2017 , 33, 44-49		10
50	Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment. 2017 , 15, 81-89		25
49	Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens. 2017 , 32, 1436-1442		26

48	Recent advances in hepatology. 2017 , 37 Suppl 1, 3-6		3
47	Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. 2017 , 11, 317-370		955
46	Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis. 2017 , 17, 46		36
45	Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. <i>Journal of Hepatology</i> , 2017 , 67, 1204-1212	13.4	297
44	Eradication of hepatitis C virus profoundly prolongs survival in hepatocellular carcinoma patients receiving transarterial chemoembolization. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 1160-1167	3.4	8
43	Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment. 2017 , 23, 1690-1697		27
42	Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression. 2018 , 38, 1459-1467		21
41	Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy. <i>Journal of the Formosan Medical Association</i> , 2018 , 117, 1011-1018	3.2	7
40	Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients. 2018 , 32, 1423-1430		17
39	Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort. <i>Journal of the Formosan Medical Association</i> , 2018 , 117, 54-62	3.2	2
38	Interference of hepatitis B virus dual infection in platelet count recovery in chronic hepatitis C patients with curative antiviral therapy. 2018 , 33, 1108-1114		4
37	Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection. <i>PLoS ONE</i> , 2018 , 13, e0202650	3.7	11
36	Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 2435-2443	5.1	12
35	An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions. <i>Journal of Hepatology</i> , 2018 , 67, 1204-1212	7	10
34	Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. <i>Journal of the Formosan Medical Association</i> , 2019 , 118, 556-564	3.2	8
33	Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders. <i>Journal of the Formosan Medical Association</i> , 2019 , 118, 504-513	3.2	6
32	Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma. <i>Cancers</i> , 2019 , 12,	6.6	4
31	Treatment of chronic hepatitis C regiments containing with recombinant interferon in patients with sustained virological response predicts risk of hepatocellular carcinoma: A meta-analysis. <i>Medicine (United States)</i> , 2020 , 99, e22435	1.8	0

30	Clusters of Circulating let-7 Family Tumor Suppressors Are Associated with Clinical Characteristics of Chronic Hepatitis C. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	2
29	Real-world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor-based therapies. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 1190-1201	3.4	0
28	Screening for Hepatitis C Virus Infection in Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. <i>JAMA - Journal of the American Medical Association</i> , 2020 ,	27.4	28
27	Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies. <i>Current HIV/AIDS Reports</i> , 2020 , 17, 6-17	5.9	6
26	The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , 2021 , 120, 965-973	3.2	5
25	Current impact of viral hepatitis on liver cancer development: The challenge remains. <i>World Journal of Gastroenterology</i> , 2021 , 27, 3556-3567	5.6	2
24	Long-term effectiveness of population-wide multifaceted interventions for hepatocellular carcinoma in Taiwan. <i>Journal of Hepatology</i> , 2021 , 75, 132-141	13.4	3
23	Long-term Risk of Hepatocellular Carcinoma Following Direct-Acting Antiviral Therapy in Compensated Liver Cirrhosis Induced by Hepatitis C Virus Infection. <i>Hepatitis Monthly</i> , 2021 , 21,	1.8	
22	Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it?. <i>World Journal of Gastroenterology</i> , 2021 , 27, 5536-5554	5.6	3
21	Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin. <i>PLoS ONE</i> , 2012 , 7, e52048	3.7	22
20	Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients. <i>PLoS ONE</i> , 2013 , 8, e58882	3.7	12
19	Interferon-based therapy decreases risks of hepatocellular carcinoma and complications of cirrhosis in chronic hepatitis C patients. <i>PLoS ONE</i> , 2013 , 8, e70458	3.7	28
18	Concerted action of IFN- α and IFN- γ induces local NK cell immunity and halts cancer growth. <i>Oncotarget</i> , 2016 , 7, 49259-49267	3.3	18
17	Post-treatment alpha fetoprotein and platelets predict hepatocellular carcinoma development in dual-infected hepatitis B and C patients after eradication of hepatitis C. <i>Oncotarget</i> , 2018 , 9, 12240-12249	2.3	4
16	Prevention of Hepatocellular Carcinoma. 2009 , 36-61		2
15	No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients. <i>Clinical and Molecular Hepatology</i> , 2014 , 20, 177-84	6.9	4
14	Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis. <i>World Journal of Hepatology</i> , 2013 , 5, 521-7	3.4	4
13	Association between IPTA gene polymorphisms and hematological abnormalities in hepatitis C virus-infected patients receiving combination therapy. <i>Gut and Liver</i> , 2015 , 9, 214-23	4.8	4

12	Postoperative Interferon Alpha Treatment of Patients with Hepatocellular Carcinoma: Expression of p48 Using Tissue Microarray. 2009 , 303-310		
11	Antiviral therapy in patients after treatment for hepatitis C-related hepatocellular carcinoma. <i>Gut and Liver</i> , 2011 , 5, 77-81	4.8	
10	The Impact of Treating Chronic Liver Diseases on Hepatocellular Carcinoma Prevention. 2012 , 229-246		
9	ERADICATION OF HCV INFECTION IN PATIENTS WITH LIVER CIRRHOSIS: FACTOR OF CANCER PREVENTION OR CARCINOGENESIS?. <i>Siberian Journal of Oncology</i> , 2019 , 18, 90-96	0.3	
8	Liver Cancer. 2020 , 341-368		
7	Hepatitis C and hepatitis B coinfection. 2020 , 182-188		1
6	Interferon-Based Therapy for Hepatitis C Virus Infections. 2008 , 168-191		
5	Surveillance and prevention of hepatocellular carcinoma. 2008 , 239-251		
4	Hepatocellular carcinoma incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis.. <i>Hepatology</i> , 2022 ,	11.2	0
3	Secular Trends of Clinical Characteristics and Survival of Hepatocellular Carcinoma in Taiwan from 2011 to 2019. 2023 , 15, 126		1
2	HIV: hepatic manifestations of HIV and antiretroviral therapy. 2023 , 525-555		0
1	Above-Standard Survival of Hepatocellular Carcinoma as the Final Outcome of Comprehensive Hepatology Care Programs in a Remote HCV-Endemic Area. 2023 , 15, 786		0